Embecta Eyes Move From Insulin Delivery to Medical Supplies Focus

embecta to Showcase Phased Approach for Value Creation and Present Long Range Financial Plan at 2025 Analyst and Investor Day - Embecta (NASDAQ:EMBC)

PARSIPPANY, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta"; "The Company") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host its inaugural Analyst and Investor Day today to showcase its phased approach for value creation and present its long range financial plan ("LRP"). "Our Investor Day will provide a comprehensive view of our roadmap for transitioning embecta to growth. We loo…

Embecta eyes move from insulin delivery to medical supplies focus

Embecta (Nasdaq:EMBC) today revealed its phased plan to create value and shift priorities toward broader medical applications. The pure-play diabetes technology company has endured ups and downs since its 2022 spin-off from BD. That includes an FDA approval for a disposable insulin patch pump system in September 2024, only to be followed by the discontinuation of its insulin patch pump program. That included a restructuring effort that led to th…